Omnicell, Inc. 10-Q Summary: Quarter Ended September 30, 2001
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended September 30, 2001, and the nine-month period ended on the same date. Omnicell, Inc. provides clinical infrastructure and workflow automation solutions, primarily pharmacy and supply systems, to healthcare facilities. The company completed its Initial Public Offering (IPO) in August 2001, raising approximately $42.9 million net of expenses. As of the reporting date, the company had installed or released 20,503 systems in 1,208 healthcare facilities.
Key Financial Metrics
| Metric (in thousands) | 3 Months Ended Sep 30, 2001 | 9 Months Ended Sep 30, 2001 | 9 Months Ended Sep 30, 2000 |
|---|---|---|---|
| Total Revenues | $22,679 | $62,506 | $48,053 |
| Gross Profit | $14,320 | $38,746 | $28,566 |
| Gross Margin % | 63.1% | 62.0% | 59.4% |
| Net Income (Loss) | $491 | $(2,565) | $(19,307) |
| Operating Cash Flow | N/A | $(11,142) | $(18,916) |
| Cash & Equivalents (Balance Sheet) | $24,619 | $24,619 | $9,681 (Dec 31, 2000) |
| Debt (Notes Payable) | $0 | $0 | $8,413 (Dec 31, 2000) |
Note: The company reported a net income of $491,000 for the quarter, marking a turnaround from a net loss of $7.4 million in the same period in 2000. However, the nine-month period still reflects a net loss of $2.6 million.
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 31.9% year-over-year for the quarter and 30.1% for the nine-month period. Product revenues grew 27.3% (quarter) and 29.5% (nine months), driven by an increase in installed systems. Service revenues grew 65.9% (quarter) and 33.9% (nine months), aided by a larger installed base and one-time revenue recoveries of $840,000 and $1.2 million for prior periods.
- Profitability: The company achieved operating income of $457,000 for the quarter, compared to an operating loss of $6.9 million in the prior year quarter. This improvement was driven by revenue growth and a reduction in operating expenses.
- Expense Reduction: Selling, general, and administrative (SG&A) expenses decreased 6.9% for the quarter and 10.8% for the nine months, largely due to reduced spending on the internet-based procurement application and the absence of a $1.1 million write-off of offering costs incurred in the prior year.
- Liquidity: Cash and cash equivalents increased from $9.7 million at year-end 2000 to $24.6 million at September 30, 2001, primarily due to IPO proceeds. The company repaid all outstanding notes payable ($7.9 million) using IPO proceeds.
Guidance, Outlook, and Risks
Management Commentary: Management anticipates that research and development expenses will increase modestly for the remainder of 2001, while SG&A expenses will remain at current levels. The company expects service revenues to continue growing in absolute dollars due to the expanding installed base but does not anticipate further one-time large revenue recoveries.
Outlook: The company believes its current cash balances and cash flows will satisfy anticipated needs for the next few years. However, it may require additional capital in the future, which could be dilutive.
Risks and Contingencies:
- Legal Proceedings: A customer (University of California San Francisco Medical Center) filed a third-party complaint alleging negligent misrepresentation and demanding rescission of pharmacy leases. The customer has suspended rent payments. Management believes the leases are valid and that the resolution will not have a material adverse effect.
- Market Risks: The healthcare industry faces financial constraints and consolidation. The company relies on a limited number of suppliers and third-party vendors (e.g., Commerce One) for critical components and services.
- Profitability: The company has a history of operating losses and an accumulated deficit of $95.4 million. There is no assurance that profitability will be achieved or sustained.
Key Facts for Investor Verification
- Revenue Quality: Verify the sustainability of service revenue growth, noting that a significant portion ($840k in Q3, $1.2M in YTD) was attributed to one-time billings for prior periods.
- Deferred Gross Profit: Review the $25.8 million in deferred gross profit, representing systems shipped but not yet installed. Delays in installation could impact future revenue recognition.
- Legal Exposure: Monitor the status of the litigation with the University of California San Francisco Medical Center regarding suspended lease payments.
- Cash Burn: Despite the IPO, the company burned $11.1 million in operating cash flow for the nine-month period. Verify the runway provided by the $24.6 million cash balance.
- Customer Concentration: Note that one leasing company accounted for 19.8% of accounts receivable as of September 30, 2001.